Ignite Creation Date:
2025-12-25 @ 1:21 AM
Ignite Modification Date:
2025-12-25 @ 11:30 PM
Study NCT ID:
NCT02660593
Status:
UNKNOWN
Last Update Posted:
2016-04-27
First Post:
2016-01-17
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Efficacy and Safety ofSanGrow Decoction for Patients With Diabetes
Sponsor:
Shidaihuajing Institute for Diabetic Research
Organization:
Study Overview
Official Title:
SanGrow Decoction in Patients With Diabetes- Single Center, Open, and Non-randomized Study
Status:
UNKNOWN
Status Verified Date:
2016-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
MedlinePlus related topics: Blood Sugar
Primary Outcome Measures:
* Fast glucose and HbA1c change between the baseline and end of study \[ Time Frame: From baseline to 30 and 100 days\]
* \[ Designated as safety issue: No \]
* Successful rate of blood glucose control (the proportion of patients with HbA1c \<7%) \[ Time Frame: From baseline to 30 days and 100 days\] \[ Designated as safety issue: No \]
Secondary Outcome Measures:
• To evaluate the change of quality of life in the 1 months by the health questionnaire SF-36 \[ Time Frame: From baseline to month 1 \] \[ Designated as safety issue: No \]
Primary Outcome Measures:
* Fast glucose and HbA1c change between the baseline and end of study \[ Time Frame: From baseline to 30 and 100 days\]
* \[ Designated as safety issue: No \]
* Successful rate of blood glucose control (the proportion of patients with HbA1c \<7%) \[ Time Frame: From baseline to 30 days and 100 days\] \[ Designated as safety issue: No \]
Secondary Outcome Measures:
• To evaluate the change of quality of life in the 1 months by the health questionnaire SF-36 \[ Time Frame: From baseline to month 1 \] \[ Designated as safety issue: No \]
Detailed Description:
This study is aimed to evaluate the safety and efficacy of Sangrow Decotion, diet and exercise for the treatment of type 2 diabetes. Previous study has shown that this therapeutic regimen is safe and effective.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: